Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01372826 · ClinicalTrials.gov registry record · Phase 1
Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01372826 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT01372826, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.
Interventions
- DRUG NKTR118 Group1
- DRUG NKTR118 Group 2
- DRUG NKTR118 Group3
- DRUG NKTR118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01372826
The ClinicalTrials.gov registry entry for NCT01372826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NKTR118 Group1 is the first listed.
NCT01372826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01372826 about?
NCT01372826 is a clinical study titled "Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function". This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.
What is the current status of trial NCT01372826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01372826?
The interventions under investigation include: NKTR118 Group1 (DRUG), NKTR118 Group 2 (DRUG), NKTR118 Group3 (DRUG), NKTR118 (DRUG).
Who is sponsoring clinical trial NCT01372826?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.